ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of BEPOSONE
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced it has initiated a Phase 2 clinical study of its BEPOSONE™ nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of the combination nasal spray, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.
ISTA expects to enroll approximately 600 patients in Texas who will be treated with either the bepotastine besilate-steroid combination nasal spray, nasal spray containing only one of the active agents, or placebo nasal spray for two weeks. Patients will grade both individual nasal and ocular symptoms on a daily basis during the treatment period.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.